Taysha Gene Therapies opened lower at $4.23, compared with its previous close of $4.28. In the last trading session, the stock traded between $4.04 and $4.43. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Taysha Gene Therapies is now worth
$ 28.11
Resulting in a loss of
$ 71.89 (71.89%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.06 (-1.47%)
Day High
$4.43
Day Low
$4.04
Day Open
$4.23
Prev Close
$4.28
Volume
32,60,957
1W Return
-3.48%
1M Return
1.98%
3M Return
-36.77%
6M Return
-38.17%
1Y Return
-1.47%
Fundamentals
Market Cap ($ Mn)
1,374
PE Ratio
-
PB Ratio
4.85
PEG Ratio
-
ROE
-64.78%
ROCE
-50.81%
EPS (TTM)
$-0.14
Investment Returns
1 Week
-3.48%
1 Month
1.98%
3 Months
-36.77%
6 Months
-38.17%
9 Months
-9.51%
Financials
Quarterly
All values in $ Mn
2.0
Dec 24
2.3
Mar 25
2.0
Jun 25
0.0
Sep 25
5.5
Dec 25
0.0
Jun 26
Updates
2Oct
Taysha Gene Therapies grants RSUs and options to four new hires
Granted 384,000 RSUs and options for 92,400 shares to four new employees. Stock option exercise price set at $4.74, matching closing price on grant date. Awards issued under 2023 Inducement Plan per Nasdaq Listing Rule 5635(c)(4). RSUs vest annually over four years; options vest over four years with monthly installments after year one.
1mo ago
12Aug
Taysha Gene Therapies Q2 EPS misses estimates as net loss widens
Taysha Gene Therapies missed Q2 EPS estimates with a loss of $(0.13) per share versus a $(0.12) consensus, while net loss widened to $46.6 million. The results reflect heavy investment in R&D for its lead candidate TSHA-102, though cash reserves strengthened to $455.4 million via equity financing.
3mo ago
3Aug
Taysha, Catalent secure commercial manufacturing for TSHA-102
Taysha Gene Therapies and Catalent signed a commercial supply agreement for TSHA-102, a gene therapy for Rett syndrome. Catalent will manufacture the drug at its Harmans, Maryland facility, leveraging its experience in over 90 gene therapy programs. The deal supports Taysha’s launch readiness as BLA-enabling activities proceed.
3mo ago
21Jul
Goldman Sachs raises Taysha Gene Therapies target to $13
Goldman Sachs analyst Salveen Richter maintained a Buy rating on Taysha Gene Therapies and raised the price target to $13 from $11, citing a revised valuation outlook.
3mo ago
2Jul
Citizens reiterates Market Outperform on Taysha Gene Therapies
Citizens analyst Silvan Turkcan has reiterated a Market Outperform rating on Taysha Gene Therapies. The firm maintains a price target of $11.
4mo ago
30Jun
Baird raises Taysha Gene Therapies price target to $15
Baird analyst Jack Allen maintained an Outperform rating for Taysha Gene Therapies and raised the price target to $15 from $12, reflecting a more optimistic outlook on the stock's potential.
